PMID- 16522812
OWN - NLM
STAT- MEDLINE
DCOM- 20070817
LR  - 20240324
IS  - 0006-4971 (Print)
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
VI  - 108
IP  - 1
DP  - 2006 Jul 1
TI  - Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: 
      review and recommendations for harmonizing current methodology for detecting 
      BCR-ABL transcripts and kinase domain mutations and for expressing results.
PG  - 28-37
AB  - The introduction in 1998 of imatinib mesylate (IM) revolutionized management of 
      patients with chronic myeloid leukemia (CML) and the second generation of 
      tyrosine kinase inhibitors may prove superior to IM. Real-time quantitative 
      polymerase chain reaction (RQ-PCR) provides an accurate measure of the total 
      leukemiacell mass and the degree to which BCR-ABL transcripts are reduced by 
      therapy correlates with progression-free survival. Because a rising level of 
      BCR-ABL is an early indication of loss of response and thus the need to reassess 
      therapeutic strategy, regular molecular monitoring of individual patients is 
      clearly desirable. Here we summarize the results of a consensus meeting that took 
      place at the National Institutes of Health (NIH) in Bethesda in October 2005. We 
      make suggestions for (1) harmonizing the differing methodologies for measuring 
      BCR-ABL transcripts in patients with CML undergoing treatment and using a 
      conversion factor whereby individual laboratories can express BCR-ABL transcript 
      levels on an internationally agreed scale; (2) using serial RQ-PCR results rather 
      than bone marrow cytogenetics or fluorescence in situ hybridization (FISH) for 
      the BCR-ABL gene to monitor individual patients responding to treatment; and (3) 
      detecting and reporting Philadelphia (Ph) chromosome-positive subpopulations 
      bearing BCR-ABL kinase domain mutations. We recognize that our recommendations 
      are provisional and will require revision as new evidence emerges.
FAU - Hughes, Timothy
AU  - Hughes T
AD  - Institute of Medical and Veterinary Science, Adelaide, Australia.
FAU - Deininger, Michael
AU  - Deininger M
FAU - Hochhaus, Andreas
AU  - Hochhaus A
FAU - Branford, Susan
AU  - Branford S
FAU - Radich, Jerald
AU  - Radich J
FAU - Kaeda, Jaspal
AU  - Kaeda J
FAU - Baccarani, Michele
AU  - Baccarani M
FAU - Cortes, Jorge
AU  - Cortes J
FAU - Cross, Nicholas C P
AU  - Cross NC
FAU - Druker, Brian J
AU  - Druker BJ
FAU - Gabert, Jean
AU  - Gabert J
FAU - Grimwade, David
AU  - Grimwade D
FAU - Hehlmann, Rudiger
AU  - Hehlmann R
FAU - Kamel-Reid, Suzanne
AU  - Kamel-Reid S
FAU - Lipton, Jeffrey H
AU  - Lipton JH
FAU - Longtine, Janina
AU  - Longtine J
FAU - Martinelli, Giovanni
AU  - Martinelli G
FAU - Saglio, Giuseppe
AU  - Saglio G
FAU - Soverini, Simona
AU  - Soverini S
FAU - Stock, Wendy
AU  - Stock W
FAU - Goldman, John M
AU  - Goldman JM
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20060307
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.10.2 (Fusion Proteins, bcr-abl)
SB  - IM
CIN - Blood. 2007 Mar 1;109(5):2263; author reply 2263-4. PMID: 17312000
MH  - Drug Monitoring/*methods
MH  - Fusion Proteins, bcr-abl/*genetics
MH  - Humans
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis/drug therapy/*genetics
MH  - *Mutation
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Protein Structure, Tertiary/genetics
MH  - Protein-Tyrosine Kinases/antagonists & inhibitors/*genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction/methods/standards
MH  - Sensitivity and Specificity
PMC - PMC1895821
EDAT- 2006/03/09 09:00
MHDA- 2007/08/19 09:00
PMCR- 2007/07/01
CRDT- 2006/03/09 09:00
PHST- 2006/03/09 09:00 [pubmed]
PHST- 2007/08/19 09:00 [medline]
PHST- 2006/03/09 09:00 [entrez]
PHST- 2007/07/01 00:00 [pmc-release]
AID - S0006-4971(20)64915-1 [pii]
AID - 0028 [pii]
AID - 10.1182/blood-2006-01-0092 [doi]
PST - ppublish
SO  - Blood. 2006 Jul 1;108(1):28-37. doi: 10.1182/blood-2006-01-0092. Epub 2006 Mar 7.